G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 15-22

  Cho, Nam Hoon ^a   Lim, Shin Young ^a   Kim, Young Tae ^a   Kim, Dongki ^a   Kim, Young Sun ^a   Kim, Jae Wook ^a  

^a Yonsei University   (South Korea)

Author keywords

Cyclin B1; G2 checkpoint; p34cdc2; p53 polymorphism; SnaPshot

Indexed keywords

ALKALINE PHOSPHATASE; CYCLIN B1; GENOMIC DNA; POLYCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN P53; RECOMBINANT ANTIBODY; VIRUS DNA; CYCLIN B; CYCLIN DEPENDENT KINASE 1; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; REPRESSOR PROTEIN;

ALLOTYPE; CANCER RISK; CANCER SCREENING; CELL CYCLE G2 PHASE; CODON; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA PURIFICATION; DNA SEQUENCE; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCUBATION TIME; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; WART VIRUS; ARTICLE; GENETICS; HELA CELL; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CDC2 PROTEIN KINASE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CODON; CYCLIN B; DNA-BINDING PROTEINS; FEMALE; G2 PHASE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0038162291     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00198-7     Document Type: Conference Paper

References (35)

1. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:1998;229-234.
2. Helland A., Langerod A., Johnsen H., Oslen A.O., Skovlund E., Borresen-Dale A. p53 polymorphism and risk of cervical cancer. Nature. 396:1998;530-533.
3. Josefsson A.M., Magnusson P.K.E., Ylitalo N., Quarforth-Tubbin P., Ponten J., Adami H.O., et al. P53 polymorphism and risk of cervical cancer. Nature. 396:1998;531.
4. Zehbe I., Voglino G., Wilander E., Genta F., Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 354:1999;218-220.
5. Yamashita T., Yaginuma Y., Saitoh Y., Kawai K., Kurakane T., Hayashi H., et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associate squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis. 20:1999;1733-1736.
6. Tenti P., Vesentini N., Spaudo M.R., Zappatore R., Migliora P., Carnevali L., et al. P53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. Cancer Epidemiol Biomarkers Prev. 9:2000;435-438.
7. Agarastos T., Lambropoulos A.F., Constantinidis T.C., Kotsis A., Bontis J.N. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev. 9:2000;113-118.
8. Malcom E.K., Baber G.B., Boyd J.C., Stoler M.H. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol. 13:2000;373-378.
9. Maldeleine M.M., Shera K., Schwartz S.M., Daling J.R., Galloway D.A., Wipf G.C., et al. The P53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;225-227.
10. Kawaguchi H., Ohno S., Araki K., Miyazaki M., Saeki H., Watanabe M., et al. P53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res. 60:2000;2753-2755.
11. Turek L.P., Smith E.M. The genetic program of genital human papilomaviruss in infection and cancer. Obstet Gynecol Clin North Am. 23:1996;735-758.
12. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
13. Albrechtsen N., Dornreiter I., Grosse F., Kim E., Wiesmuller L., Deppert W. Maintenance of genomic integrity by p53 complementary roles for activated and non-activated p53 . Oncogene. 18:1999;7706-7717.
14. Thomas M., Pim D., Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 18:1999;7690-7700.
15. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
16. Ishiwatari H., Hayasaka N., Inoue H., Yutsudo M., Hakura A. Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts. J Med Virol. 44:1994;243-249.
17. Paules R., Levedakaou E., Wilson S., Innes C., Rhodes N., Tlsty T., et al. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 55:1995;1763-1773.
18. White A., Livanos E., Tlsty T. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8:1994;666-677.
19. Thompson D.A., Belinsky G., Chang T.H., Jones D.L., Schlegel R., Munger K. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene. 15:1997;3025-3035.
20. Thomas J.T., Laimins L.A. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol. 72:1998;1131-1137.
21. Katich S.C., Zerfass-Thome K., Hoffmann I. Regulation of the cdc25A gene by the human papillomavirus type 16 E7 oncogene. Oncogene. 20:2001;543-550.
22. Morley J.M., Bark J.E., Evans C.E., Perry J.G., Hett C.A., Tully G. Validation of mitochondrial DNA minisequencing for forensic casework. Int J Legal Med. 112:1999;2410-2418.
23. Syvanen A.C. From gels to chips "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms . Hum Mutat. 13:1999;1-10.
24. Chen J., Iannone M.A., Li M.-S., Taylor J.D., Rivers P., Nelsen A.J., et al. A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension. Genome Res. 10:2000;549-557.
25. Sauer S., Lechner D., Berlin K., Lehrach H., Escary J.-L., Fox N., et al. A novel procedure for efficient genotyping of single nucleotide polymorphisms. Nucleic Acids Res. 28:2000;E13-E13.
26. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., et al. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem. 276:2001;5570-5576.
27. Ababneh M., Gotz C., Montenarh M. Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34. Biochem Biophys Res Commun. 283:2001;507-512.
28. Wagner P., Fuchs A., Nastainczyk W., Gotz C., Montenarh M. Fine mapping and regulation of the association of p53 and p34cdc2. Oncogene. 16:1998;105-111.
29. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene. 20:2001;1803-1815.
30. Bailly E., Doree M.P.N., Bornens M. p34 is located in both nucleus and cytoplasm part is centrosomally associated at G2/M and enters vesicles at anaphase . EMBO J. 8:1989;3989-3995.
31. Pines J., Hunter Y. Cyclin A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol. 115:1991;1-17.
32. Jackman M., Firth M., Pines J. Human cyclin B1 and B2 are localized to strikingly different structures B1 to microtubules, B2 primarily to the Golgi apparatus . EMBO J. 14:1995;1646-1654.
33. Jackman M.R., Pines J.N. Cyclins and the G2/M transition. Cancer Surv. 29:1997;47-73.
34. Kawamoto H., Koizumi H., Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions. Am J Pathol. 150:1997;15-23.
35. Murray A.W., Solomon M.J., Kirschner M.W. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. Nature. 339:1989;280-285.